Mark Breidenbach
Stock Analyst at Oppenheimer
(1.71)
# 3,226
Out of 4,893 analysts
56
Total ratings
32.2%
Success rate
0.72%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Breidenbach
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NRIX Nurix Therapeutics | Maintains: Outperform | $27 → $30 | $13.18 | +127.62% | 4 | Sep 4, 2024 | |
| ALLO Allogene Therapeutics | Maintains: Outperform | $14 → $13 | $1.21 | +974.38% | 5 | May 21, 2024 | |
| EPIX ESSA Pharma | Reiterates: Outperform | $17 | $1.71 | +894.15% | 5 | Dec 13, 2023 | |
| ARVN Arvinas | Reiterates: Outperform | $95 | $8.23 | +1,054.31% | 6 | Aug 9, 2023 | |
| IMRX Immuneering | Reiterates: Outperform | $25 | $4.45 | +461.80% | 3 | Aug 8, 2023 | |
| CUE Cue Biopharma | Assumes: Outperform | $10 | $0.78 | +1,176.65% | 6 | Jun 26, 2023 | |
| MCRB Seres Therapeutics | Assumes: Outperform | $240 | $12.38 | +1,838.61% | 4 | Jun 26, 2023 | |
| BLRX BioLineRx | Reiterates: Outperform | $160 | $4.92 | +3,152.03% | 1 | May 25, 2023 | |
| CGEN Compugen | Maintains: Outperform | $8 → $7 | $1.67 | +319.16% | 7 | May 16, 2023 | |
| CRBU Caribou Biosciences | Maintains: Outperform | $36 → $32 | $1.75 | +1,728.57% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $15 | $1.99 | +653.77% | 7 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 → $120 | $1.24 | +9,577.42% | 4 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11,250 → $9,750 | $3.11 | +313,404.82% | 2 | May 12, 2020 |
Nurix Therapeutics
Sep 4, 2024
Maintains: Outperform
Price Target: $27 → $30
Current: $13.18
Upside: +127.62%
Allogene Therapeutics
May 21, 2024
Maintains: Outperform
Price Target: $14 → $13
Current: $1.21
Upside: +974.38%
ESSA Pharma
Dec 13, 2023
Reiterates: Outperform
Price Target: $17
Current: $1.71
Upside: +894.15%
Arvinas
Aug 9, 2023
Reiterates: Outperform
Price Target: $95
Current: $8.23
Upside: +1,054.31%
Immuneering
Aug 8, 2023
Reiterates: Outperform
Price Target: $25
Current: $4.45
Upside: +461.80%
Cue Biopharma
Jun 26, 2023
Assumes: Outperform
Price Target: $10
Current: $0.78
Upside: +1,176.65%
Seres Therapeutics
Jun 26, 2023
Assumes: Outperform
Price Target: $240
Current: $12.38
Upside: +1,838.61%
BioLineRx
May 25, 2023
Reiterates: Outperform
Price Target: $160
Current: $4.92
Upside: +3,152.03%
Compugen
May 16, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $1.67
Upside: +319.16%
Caribou Biosciences
Mar 10, 2023
Maintains: Outperform
Price Target: $36 → $32
Current: $1.75
Upside: +1,728.57%
Mar 1, 2023
Maintains: Outperform
Price Target: $25 → $15
Current: $1.99
Upside: +653.77%
Oct 18, 2022
Maintains: Outperform
Price Target: $90 → $120
Current: $1.24
Upside: +9,577.42%
May 12, 2020
Maintains: Outperform
Price Target: $11,250 → $9,750
Current: $3.11
Upside: +313,404.82%